ATE350032T1 - Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen - Google Patents

Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen

Info

Publication number
ATE350032T1
ATE350032T1 AT99932296T AT99932296T ATE350032T1 AT E350032 T1 ATE350032 T1 AT E350032T1 AT 99932296 T AT99932296 T AT 99932296T AT 99932296 T AT99932296 T AT 99932296T AT E350032 T1 ATE350032 T1 AT E350032T1
Authority
AT
Austria
Prior art keywords
inhibitors
pain
protein kinase
epsilone
epsilon
Prior art date
Application number
AT99932296T
Other languages
English (en)
Inventor
Robert O Messing
Jon D Levine
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE350032T1 publication Critical patent/ATE350032T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
AT99932296T 1998-07-06 1999-07-06 Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen ATE350032T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9175598P 1998-07-06 1998-07-06
US10376398P 1998-10-09 1998-10-09

Publications (1)

Publication Number Publication Date
ATE350032T1 true ATE350032T1 (de) 2007-01-15

Family

ID=26784298

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99932296T ATE350032T1 (de) 1998-07-06 1999-07-06 Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen

Country Status (10)

Country Link
EP (1) EP1093379B1 (de)
JP (1) JP2002519391A (de)
AT (1) ATE350032T1 (de)
AU (1) AU764760B2 (de)
CA (1) CA2336709A1 (de)
DE (1) DE69934689T2 (de)
ES (1) ES2283120T3 (de)
IL (1) IL140716A0 (de)
NZ (1) NZ508767A (de)
WO (1) WO2000001415A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790192B2 (en) 1998-08-14 2010-09-07 Accessclosure, Inc. Apparatus and methods for sealing a vascular puncture
WO2003089456A2 (en) 2002-04-22 2003-10-30 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase c
US6933275B2 (en) 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
AU2003241559A1 (en) * 2003-05-16 2004-12-13 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase c peptides for use in withdrawal
US8598146B2 (en) 2003-09-16 2013-12-03 Garvan Institute Of Medical Research Methods for identifying modulators of protein kinase C-epsilon (PKCε) and method of treatment of aberrant glucose metabolism associated therewith
EP1869209A2 (de) * 2005-03-07 2007-12-26 Laurence Faure Auffindbarkeit von zellzyklusanomalien mit onkologie und neurodegeneration als ziel
WO2006106492A2 (en) * 2005-04-02 2006-10-12 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Assays for determining compounds which modulate tram phosphorylation
JP5143729B2 (ja) 2005-06-29 2013-02-13 ハダジット メディカル リサーチ サービシズ アンド ディベラップメント リミテッド インスリン抵抗性及び2型糖尿病の予防のためのプロテインキナーゼc阻害剤
EP2177510A1 (de) 2008-10-17 2010-04-21 Universität des Saarlandes Allosterische Proteinkinasemodulatoren
JP2010090176A (ja) * 2010-01-26 2010-04-22 Board Of Trustees Of The Leland Stanford Junior Univ 離脱症状における使用のためのプロテインキナーゼcペプチド
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
WO2014081029A1 (ja) * 2012-11-26 2014-05-30 学校法人近畿大学 抗がん剤による末梢神経障害の予防、治療、または軽減剤
WO2016003450A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Pkc-epsilon inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141957A (en) * 1990-11-02 1992-08-25 Sphinx Pharmaceuticals Corporation 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c
US5783405A (en) * 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
WO1997015575A1 (en) * 1995-10-27 1997-05-01 Procyon Pharmaceuticals, Inc. Protein kinase c modulators. y.

Also Published As

Publication number Publication date
DE69934689D1 (de) 2007-02-15
IL140716A0 (en) 2002-02-10
JP2002519391A (ja) 2002-07-02
CA2336709A1 (en) 2000-01-13
NZ508767A (en) 2003-12-19
EP1093379B1 (de) 2007-01-03
ES2283120T3 (es) 2007-10-16
WO2000001415A2 (en) 2000-01-13
DE69934689T2 (de) 2007-10-25
EP1093379A2 (de) 2001-04-25
WO2000001415A3 (en) 2000-04-13
AU764760B2 (en) 2003-08-28
AU4863199A (en) 2000-01-24

Similar Documents

Publication Publication Date Title
GEP20043363B (en) Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
BRPI0418029A (pt) formulação de anticorpos cd40 e métodos
DE69615561D1 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
HUP0004300A2 (hu) (S)-N-Etil-3-[1-(dimetil-amino)-etil]-N-metil-fenil-karbamátot és antioxidánst tartalmazó gyógyszerkészítmény
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
MX9803563A (es) Preparacion terapeutica para la administracion transdermica de principios activos.
NO980700D0 (no) Perifert aktive anti-hyperalgesi opiater
AU6257798A (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
DE69616375D1 (de) Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE59401401D1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
AU4923093A (en) Inhibitors of metazoan parasite proteases
ATE385807T1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
BRPI0411364A (pt) compostos tendo atividade inibidora de fosfatidilinositol 3-cinase e métodos de uso dos mesmos
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
PL342063A1 (en) Treatment of papular lymphomas using inhibitors of lymphotoxin path
DK0876158T3 (da) Ny medicinsk anvendelse af en ACE-inhibitor til behandling af mavesurhedssymptomer
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
ATE280575T1 (de) Transdermales therapeutisches system zur anwendung von candesartan
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
MXPA03010451A (es) Nuevos metodos para el tratamiento y prevencion del dolor.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties